HLTHMGMT 717
Biotechnology and Pharmaceutical Strategy
David Blaine RidleyNotable faculty
Co-proposed the FDA priority review voucher in Health Affairs (2006); Congress created the program in 2007. Source
Why it's on my list
David Ridley co-proposed the FDA priority review voucher in 2006. Congress enacted it the next year.
My note, not Duke's.
Description from DukeHub
This course examines a number of economic issues relating to innovation, competition, and regulation in the pharmaceutical industry and their role in management decision making. We concentrate on factors that distinguish pharmaceuticals from other industries such as its strong research intensity, broader ties to the health care system, and the critical role of government regulations and policy. The overall perspective is international, but the emphasis is on current market and policy developments in the United States. This course is for Daytime MBA and Accelerated Daytime MBA students.
Skills
- policy and lawdescription: "regulation" and 4 more
- leadershiptitle: "strategy"
AI-resilient: 1 of 5
- No: Physical, lab or field work
- No: Live work with people
- Yes: Judgment someone is accountable for · "strategy"
- No: A craft you practice with your hands or body
- No: Small, in-person format
The checks lean on Microsoft Research, Working with AI (2025), which found generative AI applies least to physical work and hands-on work with people. A signal, not a promise. How the score works
More in HLTHMGMT
- Health Sector Management Seminar I HLTHMGMT 705E
- Health Sector Management Seminar II HLTHMGMT 706
- Health Sector Strategy and Innovation HLTHMGMT 711
- Health Sector Strategy and Innovation HLTHMGMT 711E
- The Marketing of Health and Wellness HLTHMGMT 715
- Management of Health Systems and Policy HLTHMGMT 716